Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous ...

Solriamfetol is Axsome’s dopamine and norepinephrine reuptake inhibitor (DNRI), TAAR1 agonist, and 5-HT 1A agonist being developed for the treatment of attention deficit hyperactivity disorder ...

In addition to its pipeline candidates, Axsome also has US rights to Jazz Pharma's dual-acting dopamine and norepinephrine reuptake inhibitor Sunosi (solriamfetol), used to improve wakefulness in ...

Dopamine agonists may be useful in depression associated (or not) with PD and pramipexole has been demonstrated to have the same efficacy of selective serotonin-reuptake inhibitors (SSRIs).

Best supplements for supporting female libido - Help tackle factors from stress to hormones that can impact sexual desire ...

The table below is a review of notable updates that occurred in April 2025 for investigational products in development (not an inclusive list). Click on the status to view our full coverage. Drug ...

Axsome beat Q1 expectations with $121.5 million in revenue and strong Auvelity sales as it prepares Symbravo's U.S. launch ...

U.S. Customs officers at the Nogales Port of Entry recently intercepted a large quantity of drugs attempting to be smuggled ...

Fast Track designation Fam-trastuzumab deruxtecan-nxki (AstraZeneca) HER2-directed antibody + topoisomerase inhibitor conjugate First-line treatment of patients with human epidermal growth factor ...